[go: up one dir, main page]

WO2012040651A3 - Controlled release formulations of opioids - Google Patents

Controlled release formulations of opioids Download PDF

Info

Publication number
WO2012040651A3
WO2012040651A3 PCT/US2011/053132 US2011053132W WO2012040651A3 WO 2012040651 A3 WO2012040651 A3 WO 2012040651A3 US 2011053132 W US2011053132 W US 2011053132W WO 2012040651 A3 WO2012040651 A3 WO 2012040651A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
opioids
release formulations
opioid
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/053132
Other languages
French (fr)
Other versions
WO2012040651A2 (en
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Joseph Berry
Felix De La Iglesia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QRxPharma Ltd
Original Assignee
QRxPharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/024,319 external-priority patent/US20110195989A1/en
Application filed by QRxPharma Ltd filed Critical QRxPharma Ltd
Priority to AU2011305161A priority Critical patent/AU2011305161A1/en
Priority to CA2812570A priority patent/CA2812570A1/en
Priority to EP11764653.9A priority patent/EP2618820A2/en
Priority to JP2013530379A priority patent/JP2013537915A/en
Priority to CN2011800562785A priority patent/CN103476403A/en
Publication of WO2012040651A2 publication Critical patent/WO2012040651A2/en
Publication of WO2012040651A3 publication Critical patent/WO2012040651A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
PCT/US2011/053132 2010-09-24 2011-09-23 Controlled release formulations of opioids Ceased WO2012040651A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2011305161A AU2011305161A1 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
CA2812570A CA2812570A1 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
EP11764653.9A EP2618820A2 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids
JP2013530379A JP2013537915A (en) 2010-09-24 2011-09-23 Opioid controlled release formulations
CN2011800562785A CN103476403A (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38622710P 2010-09-24 2010-09-24
US61/386,227 2010-09-24
US13/024,319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids
US13/024,319 2011-02-09

Publications (2)

Publication Number Publication Date
WO2012040651A2 WO2012040651A2 (en) 2012-03-29
WO2012040651A3 true WO2012040651A3 (en) 2012-05-18

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053132 Ceased WO2012040651A2 (en) 2010-09-24 2011-09-23 Controlled release formulations of opioids

Country Status (6)

Country Link
EP (1) EP2618820A2 (en)
JP (1) JP2013537915A (en)
CN (1) CN103476403A (en)
AU (1) AU2011305161A1 (en)
CA (1) CA2812570A1 (en)
WO (1) WO2012040651A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
DE602004031096D1 (en) 2003-03-26 2011-03-03 Egalet As MORPHINE SYSTEM WITH CONTROLLED RELEASE
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
AU2013204592A1 (en) * 2012-04-09 2013-10-24 QRxPharma Ltd. Controlled release formulations of opioids
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
DK3169315T3 (en) * 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
IL273627B2 (en) 2017-12-20 2025-03-01 Purdue Pharma Lp Abuse deterrent morphine sulfate dosage forms
CN114515282B (en) * 2020-11-19 2023-09-08 山东大学 Application of Sorbic acid in preparation of anti-coronavirus infection drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CA2593165A1 (en) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Analgesic conjugates
MX2007011977A (en) * 2005-03-28 2007-12-07 Orexo Ab New pharmaceutical compositions useful in the treatment of pain.
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN101534827A (en) * 2006-11-07 2009-09-16 尼克塔治疗亚拉巴马公司 Dosage forms and co-administration of an opioid agonist and an opioid antagonist
US20090291975A1 (en) * 2008-05-20 2009-11-26 Warren Stern Dual opioid pain therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
U.S. Provisional Application Ser. No. 61/302,698 filed Feb. 9, 2010 *

Also Published As

Publication number Publication date
AU2011305161A1 (en) 2013-05-09
WO2012040651A2 (en) 2012-03-29
CA2812570A1 (en) 2012-03-29
EP2618820A2 (en) 2013-07-31
CN103476403A (en) 2013-12-25
JP2013537915A (en) 2013-10-07

Similar Documents

Publication Publication Date Title
WO2012040651A3 (en) Controlled release formulations of opioids
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL251083B (en) Compounds and compositions for the treatment of cancer
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
HUE044621T2 (en) Compounds and methods for the prevention or treatment of restenosis
SG10201405392RA (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same
IL213703A (en) Compounds for the treatment of pain and other diseases
IL225755B (en) 6-amidoderivatives of 4,5a-epoxymorphinans for treatment of pain
PL2331092T3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2013153451A3 (en) Controlled release formulations of opioids
SG10201403562UA (en) Implant for the treatment or prevention of an aneurysm
PL2493305T3 (en) 2-aminoindole compounds and methods for the treatment of malaria
GB201008792D0 (en) Apparatus for exfoliating skin and/or for the relief of itches
AU2010904906A0 (en) Methods and compositions for the treatment and prevention of skin disorders
AU2010903965A0 (en) Formulation and method for the treatment of timber
HK1189502A (en) Compositions and methods for the prevention and treatment of cancer
HK1178164A (en) Compositions and methods for the treatment of degenerative diseases
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11764653

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013530379

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2812570

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011764653

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011764653

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011305161

Country of ref document: AU

Date of ref document: 20110923

Kind code of ref document: A